Ebola virus and other emerging & RE-emerging infectious diseases
Ended Awarded Last action
- Contract number
- HHSN26100043
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $43,075,091
Award facts
- Opportunity
-
- N01CO5240180 Solicitation number
- Operations and Technical Support for the Frederick National Laboratory for Cancer Research (FLNCR), a Federally Funded Research and Development Center (FFRDC) Award Notice · Posted Apr 27, 2015
- Contract value 100% obligated
- $43,075,091.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- National Institute of Allergy and Infectious Diseases National Institutes of Health, Department of Health and Human Services
- NAICS code
- 561210 Facilities Support Services
- Set-aside
- No set-aside
- Competition
- Not Competed Only One Source
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Economy Act FAR subpart 17.5
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $43,075,091 |
About this award
This contract was awarded by the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Leidos Biomedical Research Inc., a subsidiary of Leidos Holdings, Inc. The $43,075,091.00 cost-plus-fixed-fee contract provides research, development, and production services to support studies and operations related to the Ebola virus and other emerging and re-emerging infectious diseases. Leidos Biomedical Research has served as a prime contractor and subcontractor on various NIH biomedical research efforts in the past.
Two key subcontractors on this contract are FHI Clinical Inc., which is providing clinical research infrastructure and operations support for the Partnership for Research on Ebola Virus in Liberia (PREVAIL) studies, and Mitchell Group, Inc., which is supplying operations, human resources, procurement, and logistics support. FHI 360, a nonprofit organization, is also supporting Ebola clinical monitoring efforts in the Democratic Republic of Congo as a subcontractor. This contract does not appear to have a set-aside designation.
Quick answers
Who was awarded contract HHSN26100043?
HHSN26100043 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on September 29, 2017.
How much is contract HHSN26100043 worth?
The government has obligated $43,075,091 on HHSN26100043.
Which agency awarded contract HHSN26100043?
National Cancer Institute (National Institutes of Health) awarded HHSN26100043, with funding from National Institute of Allergy and Infectious Diseases (National Institutes of Health).
Is contract HHSN26100043 an order under another contract?
Yes. HHSN26100043 is a delivery order under HHSN261201500003I, an indefinite delivery contract.
Was contract HHSN26100043 competed?
The extent of competition for HHSN26100043 was not competed.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award